Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Donnelly

Showing results (1-10 of 304) with videos related to

Pageof 31
Sort By:
International Journal of Clinical Practice. Supplement|May 18, 2001
Assessment and management of intermittent claudication: importance of secondary preventionR Donnelly
Clinical Pharmacokinetics|September 24, 1999
Clinical implications of indapamide sustained release 1.5 mg in hypertensionR Donnelly
Presse Medicale (Paris, France : 1983)|October 3, 2002
[Microalbuminuria: a therapeutic goal in patients with type 2 diabetes]R Donnelly
Journal of Cardiovascular Pharmacology|January 1, 1992
Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failureR Donnelly
Diabetes, Obesity & Metabolism|February 28, 2001
FDA reviews troglitazoneR Donnelly
International Journal of Clinical Practice|May 22, 2007
Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetesR Donnelly
The Medical Journal of Australia|November 18, 1996
The beta 3-adrenoceptor: an advance in the understanding of obesity and insulin resistanceR Donnelly
Diabetes, Obesity & Metabolism|February 28, 2001
HOPE for diabetes in the new millennium. Heart Outcomes Prevention EvaluationR Donnelly
Pediatric Nursing|May 1, 1986
Rett syndrome: what do we know about it?M R Donnelly
The Journal of Legal Medicine|March 11, 2011
The need for ibogaine in drug and alcohol addiction treatmentJennifer R Donnelly
Pageof 31

Showing results (1-10 of 304) with videos related to

Sort By:
Pageof 31
International Journal of Clinical Practice. Supplement|May 18, 2001
Assessment and management of intermittent claudication: importance of secondary preventionR Donnelly
Clinical Pharmacokinetics|September 24, 1999
Clinical implications of indapamide sustained release 1.5 mg in hypertensionR Donnelly
Presse Medicale (Paris, France : 1983)|October 3, 2002
[Microalbuminuria: a therapeutic goal in patients with type 2 diabetes]R Donnelly
Journal of Cardiovascular Pharmacology|January 1, 1992
Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failureR Donnelly
Diabetes, Obesity & Metabolism|February 28, 2001
FDA reviews troglitazoneR Donnelly
International Journal of Clinical Practice|May 22, 2007
Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetesR Donnelly
The Medical Journal of Australia|November 18, 1996
The beta 3-adrenoceptor: an advance in the understanding of obesity and insulin resistanceR Donnelly
Diabetes, Obesity & Metabolism|February 28, 2001
HOPE for diabetes in the new millennium. Heart Outcomes Prevention EvaluationR Donnelly
Pediatric Nursing|May 1, 1986
Rett syndrome: what do we know about it?M R Donnelly
The Journal of Legal Medicine|March 11, 2011
The need for ibogaine in drug and alcohol addiction treatmentJennifer R Donnelly
Pageof 31